JP2023527054A - Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 - Google Patents

Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 Download PDF

Info

Publication number
JP2023527054A
JP2023527054A JP2022572765A JP2022572765A JP2023527054A JP 2023527054 A JP2023527054 A JP 2023527054A JP 2022572765 A JP2022572765 A JP 2022572765A JP 2022572765 A JP2022572765 A JP 2022572765A JP 2023527054 A JP2023527054 A JP 2023527054A
Authority
JP
Japan
Prior art keywords
ifn
patient
type
patients
anifrolumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527054A5 (https=
Inventor
シニバルディ，ドミニク
ホワイト，ウェンディ
スミス，マイケル
ケイシー，ケリー
イレイ，ガボール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2023527054A publication Critical patent/JP2023527054A/ja
Publication of JP2023527054A5 publication Critical patent/JP2023527054A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022572765A 2020-05-29 2021-05-28 Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療 Pending JP2023527054A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031854P 2020-05-29 2020-05-29
US63/031,854 2020-05-29
PCT/EP2021/064312 WO2021239928A2 (en) 2020-05-29 2021-05-28 Treatment of cardiometabolic disease

Publications (2)

Publication Number Publication Date
JP2023527054A true JP2023527054A (ja) 2023-06-26
JP2023527054A5 JP2023527054A5 (https=) 2024-05-30

Family

ID=76269736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572765A Pending JP2023527054A (ja) 2020-05-29 2021-05-28 Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療

Country Status (10)

Country Link
US (1) US12410254B2 (https=)
EP (2) EP4157873A2 (https=)
JP (1) JP2023527054A (https=)
KR (1) KR20230018446A (https=)
CN (1) CN115667309A (https=)
AU (1) AU2021279277A1 (https=)
BR (1) BR112022023438A2 (https=)
CA (1) CA3183611A1 (https=)
IL (1) IL298299A (https=)
WO (1) WO2021239928A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
WO2022106460A2 (en) * 2020-11-18 2022-05-27 Astrazeneca Ab Steroid sparing
CN120392997A (zh) 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051066A1 (en) * 2015-08-19 2017-02-23 Medimmune, Llc Stable anti-ifnar1 formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
SG144925A1 (en) * 2003-08-04 2008-08-28 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
KR20160070165A (ko) * 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
CN107110939B (zh) * 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
FI20177098A1 (fi) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Menetelmiä ja laitejärjestelyitä diabeteksen, sydän- ja verisuonisairauksien, tulehdusten, dementian ja kuolleisuuden riskejä vähän liikkuvilla henkilöillä vähentävän liikunnan kynnysarvojen määrittämiseen
JP7013632B2 (ja) * 2018-09-18 2022-02-01 アイ－エムエービー バイオファーマ （ハンジョウ） カンパニー リミテッド 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
CA3119749A1 (en) * 2018-11-15 2020-05-22 Ampel Biosolutions, Llc Machine learning disease prediction and treatment prioritization

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051066A1 (en) * 2015-08-19 2017-02-23 Medimmune, Llc Stable anti-ifnar1 formulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
2018 ACR/ARHP ANNUAL MEETING[ONLINE],2018, vol. [検索日：2025.05.30], JPN6025024654, pages 975, ISSN: 0005748843 *
ANNALS OF THE RHEUMATIC DISEASES, vol. Vol.75, Supplement 2, JPN6025024652, 2016, pages 293 - 0295, ISSN: 0005748841 *
ANNALS OF THE RHEUMATIC DISEASES, vol. Vol.77, Supplement 2, JPN6025024653, 2018, pages 136 - 137, ISSN: 0005748842 *

Also Published As

Publication number Publication date
WO2021239928A9 (en) 2022-03-17
EP4566667A3 (en) 2025-09-03
WO2021239928A2 (en) 2021-12-02
AU2021279277A1 (en) 2023-02-02
CA3183611A1 (en) 2021-12-02
US12410254B2 (en) 2025-09-09
EP4157873A2 (en) 2023-04-05
WO2021239928A3 (en) 2022-01-27
IL298299A (en) 2023-01-01
US20240158519A1 (en) 2024-05-16
KR20230018446A (ko) 2023-02-07
EP4566667A2 (en) 2025-06-11
BR112022023438A2 (pt) 2022-12-20
CN115667309A (zh) 2023-01-31

Similar Documents

Publication Publication Date Title
Md Yusof et al. Targeting interleukin-6 in rheumatoid arthritis
JP2018109056A (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
JP7484027B2 (ja) 皮下注射のための抗ｉｆｎａｒ１投薬計画
NZ794842A (en) Methods of treating inflammatory conditions
JP5834004B2 (ja) ループス治療のための方法および組成物
JP2023527054A (ja) Ｉ型インターフェロンシグナル伝達の阻害剤による心血管代謝疾患の治療
TW202133877A (zh) 全身性紅斑狼瘡中之ｉ型干擾素抑制
JP2023546361A (ja) ループスにおける紅斑の治療
JP2025000638A (ja) 抗ＩＦＮ－α／ω抗体の投与方法
US20240368294A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
JP7475011B2 (ja) Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法
AU2022274306A1 (en) Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythematosus patients
US20220267428A1 (en) BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS
Cohen et al. Safety, tolerability, pharmacokinetic and pharmacodynamic properties of SBI-087, a CD20-directed B-cell depleting agent: Phase 1 dose escalating studies in patients with either mild rheumatoid arthritis or systemic lupus
WO2021243424A1 (en) Method of treating or preventing acute respiratory distress syndrome
JP6923594B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
IL324676A (en) Lupus treatment
JP2026513830A (ja) 用量
KR20250166150A (ko) 투여 용량
TW202430212A (zh) 狼瘡之治療
HK40076109B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WU et al. MMP-2, MMP-9 production was significantly elevated by fibroblast cells isolated from rheumatoid arthritis patient when co-cultured with monocyte (THP-1) with high levels of CD147
HK40006965B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40006965A (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251209